相似文献
1
[Retracted] Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.[已撤回] 阿那莫林对非小细胞肺癌合并恶病质患者疗效的预测因素：一项回顾性研究。
Oncol Lett. 2024 Mar 26;27(5):229. doi: 10.3892/ol.2024.14360. eCollection 2024 May.
2
Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.阿那莫林对非小细胞肺癌合并恶病质患者疗效的预测因素：一项回顾性研究。
Oncol Lett. 2023 Nov 16;27(1):22. doi: 10.3892/ol.2023.14154. eCollection 2024 Jan.
3
Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).阿那莫林（ONO-7643）治疗非小细胞肺癌合并恶液质患者的疗效：来自一项日本患者的随机、双盲、安慰剂对照、多中心研究的结果（ONO-7643-04）。
Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4.
4
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.阿那莫林治疗非小细胞肺癌合并恶液质患者的两项随机、双盲、III 期临床试验（ROMANA1 和 ROMANA2）结果
Lancet Oncol. 2016 Apr;17(4):519-531. doi: 10.1016/S1470-2045(15)00558-6. Epub 2016 Feb 20.
5
Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.阿那莫林（ONO-7643）用于日本非小细胞肺癌合并恶病质患者：一项随机2期试验的结果。
Support Care Cancer. 2016 Aug;24(8):3495-505. doi: 10.1007/s00520-016-3144-z. Epub 2016 Mar 23.
6
A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.一项关于 anamorelin（ONO-7643）治疗癌症恶病质和低体重指数患者的多中心、开放标签、单臂研究。
Cancer. 2022 May 15;128(10):2025-2035. doi: 10.1002/cncr.34154. Epub 2022 Feb 23.
7
Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study.预测恶病质胃肠癌患者对 anamorelin 反应的因素：一项回顾性研究。
Support Care Cancer. 2023 Jan 14;31(2):115. doi: 10.1007/s00520-023-07576-y.
8
ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.罗曼娜 3 期：一种增食欲素受体激动剂治疗晚期非小细胞肺癌（NSCLC）伴恶液质患者的 3 期安全性扩展研究。
Ann Oncol. 2017 Aug 1;28(8):1949-1956. doi: 10.1093/annonc/mdx192.
9
Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study.在癌症恶病质患者中,anamorelin 的疗效和安全性:一项安慰剂对照研究的事后亚组分析。
Cancer Med. 2023 Feb;12(3):2918-2928. doi: 10.1002/cam4.5206. Epub 2022 Nov 16.
10
Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia.治疗前体重减轻程度对安那莫林治疗晚期胰腺癌伴恶液质患者疗效的影响。
Intern Med. 2023 Jul 1;62(13):1887-1893. doi: 10.2169/internalmedicine.0730-22. Epub 2022 Nov 23.
Zotero 插件